Details of the Drug Combination

General Information of Drug Combination (ID: DCJXHP0)

• Drug Combination Name: PF-562271 + Nintedanib
• Indication: Hodgkin lymphoma; Status: Investigative [1]
• Component Drugs:
  PF-562271 (DMSLE03): Small molecular drug
  Nintedanib (DMMQ2OW): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: U-HO1
  Zero Interaction Potency (ZIP) Score: 0.45
  Bliss Independence Score: 3.4
  Loewe Additivity Score: 4.09
  LHighest Single Agent (HSA) Score: 5.58

Molecular Interaction Atlas of This Drug Combination

Indication(s) of PF-562271

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

PF-562271 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Focal adhesion kinase 1 (FAK)	TTON5IT	FAK1_HUMAN	Inhibitor	[6]

Indication(s) of Nintedanib

Disease Entry	ICD 11	Status	REF
Idiopathic pulmonary fibrosis	CB03.4	Approved	[3]
Non-small-cell lung cancer	2C25.Y	Approved	[4]
Ovarian neoplasm	N.A.	Approved	[4]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[5]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] ClinicalTrials.gov (NCT00666926) Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms. U.S. National Institutes of Health.
• [3] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 205832
• [4] Nintedanib FDA Label
• [5] ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health.
• [6] Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011 Nov;10(11):2135-45.